Name: Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions.
Uploaded: 2024-01-30T07:39:37.782740+00:00
Duration: 542 s
Channel: Vox Markets
Description: Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/007/008/007008/video_7Li8Z5c.mp4#t=363

Vox Markets

Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions.

Mo Khan talks through the highlights of hVIVO’s expectation-beating FY23 trading update.

How operational gearing is flowing through into a rapidly increasing Ebitda margin.

What’s behind the increase in the order book to a record £80m, including an expanded range of human challenge models and increasing contract sizes.

The outlook for 2024, including 90% of revenue already contracted and the opening of the Canary Wharf facility that expands the group’s revenue capacity to over £90m of annual revenue.

How the new facility will further support margin expansion.

The introduction of a dividend policy and the cash generative qualities of the group that underpins it.

Vox Markets talks to hVIVO chief executive Mo Khan on a year that saw the human challenge trial specialist beat previously upgraded Ebitda guidance and start 2024 with the company’s highest ever starting order book, laying a solid foundation for its next phase of growth.
0:29 Mo Khan talks through the highlights of hVIVO’s expectation-beating FY23 trading update.
1:28 How operational gearing is flowing through into a rapidly increasing Ebitda margin.
2:22 What’s behind the increase in the order book to a record £80m, including an expanded range of human challenge models and increasing contract sizes.
4:07 The outlook for 2024, including 90% of revenue already contracted and the opening of the Canary Wharf facility that expands the group’s revenue capacity to over £90m of annual revenue.
5:31 How the new facility will further support margin expansion.
6:03 Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions.
7:26 The introduction of a dividend policy and the cash generative qualities of the group that underpins it.

Vox Markets talks to hVIVO chief executive Mo Khan on a year that saw the human challenge trial specialist beat previously upgraded Ebitda guidance and start 2024 with the company’s highest ever starting order book, laying a solid foundation for its next phase of growth. 0:29 Mo Khan talks through the highlights of hVIVO’s expectation-beating FY23 trading update. 1:28 How operational gearing is flowing through into a rapidly increasing Ebitda margin. 2:22 What’s behind the increase in the order book to a record £80m, including an expanded range of human challenge models and increasing contract sizes. 4:07 The outlook for 2024, including 90% of revenue already contracted and the opening of the Canary Wharf facility that expands the group’s revenue capacity to over £90m of annual revenue. 5:31 How the new facility will further support margin expansion. 6:03 Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions. 7:26 The introduction of a dividend policy and the cash generative qualities of the group that underpins it.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/007/008/007008/video_7Li8Z5c.mp4